Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to
Just $1.99per week for the first 24weeks
Just $1.99per week for the first 24weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(}function setPanelState(o){dom.root.classList[o?"add":"remove"](,dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

Timothy Brown, who had leukemia and HIV, in San Francisco, Nov. 2, 2011. After receiving two bone marrow transplants to treat Brown's leukemia, HIV could no longer be detected in his body. Brown's experience and that of another patient has given scientists hope that a cure for AIDS may be achievable.


In the early 1980s, when the AIDS epidemic first hit, those whose immune systems were ravaged by the strange new disease lived, on average, about six months.

Today, a 25-year-old man infected by what we now know to be the human immunodeficiency virus can expect to live an additional 53 years, a woman 58 years – an almost normal life expectancy.

And, for the first time, the annual number of AIDS deaths is falling. So too is the number of newly infected.

Story continues below advertisement

What happened?

Prevention initiatives in bath houses and the community at large began, and advocacy for safer sex, human-rights protections and demands for treatment built up over time. Science also happened, in a relentless manner that is not always appreciated.

The virus, HIV, was identified in 1984. The first drug treatment, AZT (zidovudine), arrived in 1987, then two-drug therapy in 1994, and game-changing antiretroviral cocktails in 1996.

Antiretroviral therapy was a dramatic breakthrough, to the point where scientists began to cautiously whisper of a "cure." Now, though, the whisper is becoming an open conversation, though no one yet dares shout "cure" because it's not quite the right word.

True, there are several promising developments, new weapons to help control the pandemic, which were highlighted at the 19th International AIDS in Washington last week.

There was, of course, much discussion of the Berlin Patient. Timothy Ray Brown is the first – and to date only – person who has been cured of AIDS.

What happened is that he developed leukemia and, as part of the treatment, was transplanted with bone marrow. This marrow came from a donor with a genetic mutation – CCR5-Delta32 – that makes it virtually impossible for HIV to bind to cells.

Story continues below advertisement

After his treatment, Mr. Brown no longer had detectable levels of HIV in his body. He has also not taken antiretrovirals for five years. So he appears to be cured. Mr. Brown's amazing story opens the possibility of developing a vaccine based on the CCR5-Delta32 mutation, though that is still in the dreaming stage.

At the conference, scientists reported on two more men in Boston who had a similar experience: They were HIV-positive and, after receiving bone marrow transplants for leukemia, they no longer had detectable levels of the virus. But two things distinguish them from Mr. Brown: Their marrow does not have the genetic mutation and they have not stopped taking antiretrovirals.

If they do, what will happen? No one really knows. So they are sort-of-cured.

What is clear, though, is that treating HIV-infected patients with bone marrow transplants is not a practical solution. It's expensive, it's brutal and, if they don't have leukemia, it's probably not ethical.

More interesting still is another study of 14 patients in France. This small group of men and women all started drug treatment almost immediately after being infected, when levels of the virus were still very low. (Normally, treatment is only initiated when CD4 counts – a measure of the immune system waning – hit a certain level, but that threshold is coming down, for reasons that will soon become obvious.)

The French patients all took antiretrovirals for at least three years and levels of virus were undetectable in their blood. Then they stopped. Remarkably, their levels stayed down.

Story continues below advertisement

This group is being described as being "functionally cured." It has been known for a while that there are some HIV-infected patients who are "super-controllers," meaning that the virus doesn't really spread in their bodies and they remain healthy without drugs. What the Paris research shows, though, is that this super-controller status may be able to be induced with early treatment.

That, unlike bone marrow transplant, is doable and affordable.

In fact, it is a natural extension of the philosophy known as "treatment as prevention." The approach, pioneered by the B.C. Centre for Excellence in HIV/AIDS, holds that by treating the HIV-infected early and aggressively you not only keep them healthier but prevent them from spreading the disease.

If you can keep the HIV-positive from infecting others – with antiretrovirals, with condom use, with circumcision and other prevention measures – you go a long way toward reining in the epidemic.

Ideally, you would like a vaccine too (but, realistically, that's a long way off) to stop new infections, along with a simple and effective treatment for the 34 million infected.

A tall order. But the message that emerged at last week's AIDS conference is that a lot of progress is being made, at least on the science side of the equation.

Story continues below advertisement

Scientists tend to shy away from "cure" because it is a loaded term. With HIV/AIDS, we have to be careful to use the term cautiously, but appropriately.

On an individual level, there is no pill that can be given to make the virus disappear. But there is a cocktail of pills that can suppress it and stave off damage, often for decades. What we have today is an ability to control, not cure, HIV in individuals.

On a global scale, we often use the word "cure" as meaning eradication, making a pathogen disappear from circulation, as we have done with smallpox.

That's not going to happen with AIDS, at least not for a couple of generations. But we are finally taking some control over an out-of-control epidemic.

That is the first tiny step toward a cure, a beginning of the end.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the author of this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to If you want to write a letter to the editor, please forward to

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies